Summary of InMed Pharmaceuticals Q4 2022 Earnings Call

1Key Financial Results and Metrics

Net Loss: $18.6 million for the fiscal year ended June 30, 2022, compared to a net loss of $10.2 million in the previous year.

Loss Per Share: $33.17, down from $37.96 per share year-over-year.

R&D Expenses: Increased to $7.3 million from $5.3 million, primarily due to the inclusion of BayMedica's results and increased activities related to the INM-755 Phase 2 trial.

G&A Expenses: Rose by 54% to $6.9 million, attributed to BayMedica's operating results and higher costs associated with being listed on Nasdaq.

BayMedica Revenue: Generated $1.1 million in sales, reflecting challenges in the rare cannabinoid market.

Cash Position: $6.2 million as of June 30, 2022, with additional financing of approximately $5.4 million expected to support operations into the second half of fiscal 2023.

2Strategic Updates and Business Highlights

Clinical Trials: Progressing with the Phase 2 trial of INM-755 for epidermolysis bullosa (EB), now enrolling adolescents, with a data readout anticipated in Q1 2023.

INM-088 Development: Preclinical research for glaucoma is advancing, with plans to file an IND application in H1 2024.

Neurodegenerative Disease Pipeline: Filed a patent for cannabinoid treatments targeting diseases like Alzheimer's and Parkinson's, with ongoing research for potential candidates.

BayMedica Operations: Focus on launching new products and building a portfolio of rare cannabinoids, although revenue growth has been slower than expected.

3Forward Guidance and Outlook

Upcoming Catalysts: Expected completion of the Phase 2 trial for INM-755 and data readout in early 2023, IND-enabling studies for INM-088 by the end of 2023, and candidate selection for neurodegenerative diseases in Q2 2023.

Cost-Saving Measures: Implemented significant cost reductions, including a 25% workforce reduction and management salary cuts, aiming for a 30% annual savings in human resource expenses.

4Bad News, Challenges, or Points of Concern

Market Conditions: The biotech sector is facing severe capital market challenges, particularly for small-cap companies, impacting funding and operational capabilities.

BayMedica Performance: Revenue growth has been hindered by economic uncertainty and immature market conditions for rare cannabinoids, leading to a strategic reduction in commercial activities.

Impairment Charges: A non-cash impairment of $3.5 million related to BayMedica's intangible assets and goodwill was recorded due to the refocus on core pharmaceutical development.

5Notable Q&A Insights

Efficacy Data from INM-755: No specific efficacy data was reported from the independent data monitoring committee; they only confirmed safety for adolescent enrollment.

Future Trials: Management anticipates that additional trials will be necessary following the Phase 2 trial for INM-755, as the current study's data may not be sufficient for regulatory filing.

Burn Rate: The company reported a monthly burn rate of approximately $900,000, expected to decrease to around $700,000, with operational expenses projected at about $500,000 per month. This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, challenges faced, and insights from the Q&A session during InMed Pharmaceuticals' Q4 2022 earnings call.